Tag:
biotech drugs
Latest Headlines
Latest Headlines
InnaVirVax nabs $4.9M in B round to advance HIV immunotherapy
French biotech InnaVirVax has rallied investors to pump $4.9 million into its coffers via a Series B round of financing. The company will use the proceeds to begin trials of its drug VAC-3S, which is
Top 10 Blockbuster Biotech Drugs
Over the summer we took a look at the Top 15 Bestselling Drugs of 2008 . Now we're turning our attention to the biotech industry's blockbusters. As traditional pharmaceuticals face an increasing
Novartis targets biotech drugs as it boosts R&D
Novartis has gone out of its way to persuade analysts that it is going all out to advance new medications in its pipeline. There are 139 new projects in clinical studies, including 88 new molecular
UC center wants efficient biotech drug production
When the UC-Berkeley Center for Biopharmaceutical Operations opens next year, its founders plan to find more efficient methods to manufacture biologics. And their goal is to make biotech drugs less
Eli Lilly out to redesign itself as a biotech
Look for Eli Lilly to start looking more like a biotech company. That's the word from Lilly CEO-- and
Biotech godfather mulls investors' 'collapse of confidence'
The "godfather" of the UK's biotech industry has a dose of bitter news for his colleagues in drug development. Investors have suffered a "collapse of confidence" in the country's biotech companies
J&J psoriasis drug may carry cancer risk
Outside experts are preparing to review ustekinumab, Centocor's injectable treatment of severe psoriasis. Two Phase III studies demonstrated
Lilly pays $35M to land TransPharma pact
Eli Lilly is forking over a $35 million upfront payment to nail down the worldwide licensing rights to TransPharma Medical's ViaDerm-hPTH osteoporosis product and a non-exclusive license to its
SPOTLIGHT: Colorado passes $26.5M biotech incentive bill
Like so many other regions , Colorado is hoping to get its own slice of the biotech
ALSO NOTED: Meda buys late-stage drugs;Debiopharm licenses peptide;and much more...
> How might drugmakers navigate the rocky waters of generic competition, cautious regulators, safety scandals, globalization, and so on? Seek help with the itinerary from an expert, perhaps. At
